GastroIntestinal Cancer in Children and Adolescents (GICCA): a SEER Population-based Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Gastrointestinal Cancer
- Sponsor
- Paul G. Kemps, MD
- Enrollment
- 2500
- Locations
- 2
- Primary Endpoint
- Overall survival
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The goal of this observational population-based cohort study is to investigate the clinical characteristics and outcomes of children and adolescents with primary gastrointestinal malignancies registered in the publicly available Surveillance, Epidemiology, and End Results (SEER) 17 database during 2000-2019.
Detailed Description
The investigators aim to describe the patient and tumor characteristics, treatments, and outcomes of children and adolescents diagnosed with primary gastrointestinal malignancies, and to analyze these data for trends over time. In addition, the investigators want to explore independent prognostic factors for overall survival. Finally, the investigators want to describe subsequent primary malignancies diagnosed among patients from the study cohort, as well as to calculate their risk of developing a second primary cancer relative to the general population. Data on children (aged 0-17 years at diagnosis) and young people aged 18-24 years at diagnosis are analyzed separately. Special focus is laid on patients with primary carcinomas of the gastrointestinal tract; particularly colorectal carcinoma.
Investigators
Paul G. Kemps, MD
Researcher
Leiden University Medical Center
Eligibility Criteria
Inclusion Criteria
- •Age at primary gastrointestinal cancer diagnosis \<25 years
- •Diagnosis of a primary gastrointestinal malignancy as an individual's first primary malignancy
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Overall survival
Time Frame: 2000-2019
Defined as the time between the date of diagnosis and the date of death from any cause (event) or date of last follow-up.
Secondary Outcomes
- Standardized incidence of second primary malignancies(2000-2019)